Category Archives: IP Rights

German Federal Patent Court Determines License Fee for a Compulsory License under HIV Drug Patent

Source: All About IP On 21 November 2017, the German Federal Patent Court decided about a license fee for the HIV-Drug Isentress for which it has granted a compulsory license in 2016. Background of the Case In 2016, Shionogi & … Continue reading

Posted in IP Rights | Leave a comment

Perspectives on access to medicines and IP rights

Source: WIPO Magazine On average, people around the world are living significantly longer than their grandparents. In part, this is thanks to innovation in vaccines and to medicines reaching increasing numbers of patients. But as people live longer and new … Continue reading

Posted in Access to Medecines, IP Rights, IPR, Patent | Leave a comment

South Centre statement on EU-MERCOSUR trade negotiations

Source: South Centre statement on EU-MERCOSUR trade negotiations EU-MERCOSUR trade negotiations must not impose TRIPS Plus provisions on protection and enforcement of intellectual property rights. The South Centre is deeply concerned over intellectual property rights (IPRs) provisions put forward … Continue reading

Posted in EU- Mercosur FTA, IPR Enforcement, TRIPS plus, Uncategorized | Leave a comment

Section 301: US investigates allegations of forced technology transfers to China

Source: EastAsia Forum Authors: Zhiyao (Lucy) Lu and Gary Clyde Hufbauer, Peterson Institute for International Economics On 18 August 2017, the Trump administration invoked Section 301 of the Trade Act of 1974 to launch an investigation into alleged Chinese violations of intellectual … Continue reading

Posted in Seizures, Special 301 report, Uncategorized, WTO | Leave a comment

What’s at stake in Hyderabad

By Feroz Ali, The Hindu | July 28, 2017 India must counter Japan’s U.S.-style pressure at the RCEP talks and ensure affordable generic medicines Leaked texts are like leaked gases — you may never find the one responsible for it, … Continue reading

Posted in Data Exclusivity, IP Rights, IPR, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, Uncategorized | Leave a comment

A Trade Deal Could Hit Affordable & Generic Medicines in India. Here’s What You Need to Know.

If accepted the trade deal measures will delay access to affordable medicines by restricting generic competition and maintaining monopoly pricing. Published: The Better India Officials from the sixteen countries negotiating the Regional Comprehensive Economic Partnership (RCEP) trade deal – which … Continue reading

Posted in Data Exclusivity, FTA, Generic competition, Generics, IP Rights, IPR, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

The Trump Executive Order on drug prices: not what was promised nor needed, and contrary to US self interest

Source: Medium Emily Kopp has a big scoop for Kaiser Health News. She has obtained a six page document outlining the draft provisions or objectives of a proposed Presidential Executive Order (EO) on drug prices. She has shared some of … Continue reading

Posted in Compulsory Licensing, Data Exclusivity, Evergreening, IPR Enforcement, Special 301 report, Uncategorized, UNHLP report, US Pressure | Leave a comment